Intratumoral Cancer Therapies Market Outlook 2032 | Key Assessment into the Epidemiology Trends, Evolving Market Dynamics, Ongoing Therapeutic Developments, Emerging Therapies, and Prominent Players by DelveInsight

DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Intratumoral Cancer Therapies Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Intratumoral Cancer Therapies market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Intratumoral Cancer Therapies: An Overview
Intratumoral therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy that aims to use the tumor as its own vaccine. Using the tumor as a source of antigens expressed across multiple tumor clones, Intratumoral immunotherapies aim to initiate local recruitment of immune cells into the tumor microenvironment and subsequently prime T cells for a systemic polyclonal antitumor response (abscopal effect), potentially addressing Intra and inter-tumoral heterogeneity.

Multiple Intratumoral approaches, such as immune-potentiating cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, OVs, and plasmid DNA, etc. are under clinical development for melanoma patients.

Intratumoral Cancer Therapies Market Key Facts
- In 2021, the total Intratumoral Cancer Therapies Market size was approximately USD 93 million, which is expected to rise during the study period (2019-2032).
- The total Intratumoral Cancer Therapies Market size in the United States accounted for USD 21 million in 2021.
- In 2021, the total Intratumoral Cancer patient pool cases across 7MM were about 469K, which are expected to grow by 2032.
- There are different categories of Intratumoral Therapies, such as cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules. Currently, only three Intratumoral Therapies are approved; namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), approved in the US, Europe, and Japan in 2015, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021, and HENSIFY (Nanobiotix) approved in European market in 2019.
- Some of the key companies in the Intratumoral Cancer Therapeutics Market include Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicvm AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix, and others.

Intratumoral Cancer Therapies Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Intratumoral Cancer Therapies market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Intratumoral Cancer Therapies market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Intratumoral Cancer Therapies Market will Grow by 2032:
https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Intratumoral Cancer Therapies Epidemiology
The epidemiology section covers detailed insights into the historical and current Intratumoral Cancer Therapies patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Intratumoral Cancer Therapy Epidemiology, Segmented by -
- Total Incident Cases Of Selected Cancer Types (such as Melanoma, non-melanoma skin cancer, Head and Neck cancer, Pancreatic cancer, Renal cell carcinoma, Colorectal cancer, Breast Cancer, Brain Cancer, and Soft tissue sarcoma) across the 7MM [2019-2032]
- Target Patient Pool of Intratumoral Therapies by Cancer Types across the 7MM [2019-2032]
- Total Treated cases by Line of Therapies in the 7MM (2019-2032)

Intratumoral Cancer Therapies Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intratumoral Cancer Therapies market or expected to be launched during the study period. The analysis covers Intratumoral Cancer Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Intratumoral Cancer Therapies Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Intratumoral Cancer Therapeutics Assessment
The currently available treatment options for cancers include immunotherapy, radiotherapy, chemotherapy, targeted drug therapy, hormone therapy, and others. However, not all patients are able to get benefit from these therapies, as patients develop resistance to these therapies. To combat such a scenario, Intratumoral administration is the tempting and best approach for directly addressing local tumor immunity obstacles. Direct administration into specific tumor lesions has numerous advantages over systemic treatment, including higher local concentrations and perhaps fewer systemic side effects. As a result, currently, there are also plenty of Intratumoral immunotherapies in clinical studies.

As per DelveInsight, the Intratumoral Cancer Therapies Market dynamics are anticipated to evolve significantly in the coming years owing to the entry of therapies with better clinical profiles and the approval of several drugs targeting different cancer indications.

Leading Companies in the Intratumoral Cancer Therapies Market:
Some of the key companies in the Intratumoral Cancer Therapies Market include AiViva Biopharma, Amgen, Apexigen, Checkmate Pharmaceuticals, Daiichi Sankyo, DNAtrix, Exicure, Highlight Therapeutics, Hookipa Biotech GmbH, Idera Pharmaceuticals, Immunicvm AB, Immunovative Therapies, Intensity Therapeutics, Istari Oncology, Lokon Pharma AB, Merck & Co (Viralytics), Merck Sharp & Dohme Corp., Moderna Therapeutics, Momotaro-Gene, Nanobiotix, NanOlogy, Oncolys BioPharma, OncoSec Medical Incorporated, Philogen, Provectus Biopharmaceuticals, Regeneron, Replimune, SillaJen, Sirnaomics, Takara Bio, Treovir, Vyriad, Ziopharm, and many others.

Intratumoral Cancer Therapies Covered in the Report Include:
- BO-112: Highlight Therapeutics
- Cavatak: Merck (Viralytics)
- Cotsiranib (STP705): Sirnaomics
- Delytact (teserpaturev/G47∆/ DS-1647): Daiichi Sankyo
- DNX-2401: DNAtrix
- Hensify (NBTXR3/ PEP503): Nanobiotix
- Imlygic (Talimogene laherparepvec; T-VEC): Amgen
- INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
- Intuvax (Ilixadencel): Immunic#m AB
- LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
- MK-1454: Merck Sharp & Dohme Corp.
- NanoPac (LSAM Paclitaxel): NanOlogy
- Nidlegy: Philogen
- RP1 (Vusolimogene Oderparepvec): Replimune
- Tavokinogene telseplasmid (Tavo): OncoSec Medical Incorporated
- Vidutolimod (CMP-001): Checkmate Pharmaceuticals
- Voyager-V1 [VV1]: Vyriad
And Many More

Learn More About the Emerging Therapies & Key Companies in the Intratumoral Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Intratumoral Cancer Therapies Competitive Intelligence Analysis
4. Intratumoral Cancer Therapies Market Overview at a Glance
5. Intratumoral Cancer Therapies Background and Overview
6. Intratumoral Cancer Therapies Patient Journey
7. Intratumoral Cancer Therapies Epidemiology and Patient Population
8. Intratumoral Cancer Therapies Treatment Algorithm, Current Treatment, and Medical Practices
9. Intratumoral Cancer Therapies Unmet Needs
10. Key Endpoints of Intratumoral Cancer Therapies Treatment
11. Intratumoral Cancer Therapies Marketed Products
12. Intratumoral Cancer Therapies Emerging Therapies
13. Intratumoral Cancer Therapies Seven Major Market Analysis
14. Attribute Analysis
15. Intratumoral Cancer Therapies Market Outlook (7 major markets)
16. Intratumoral Cancer Therapies Access and Reimbursement Overview
17. KOL Views on the Intratumoral Cancer Therapies Market.
18. Intratumoral Cancer Therapies Market Drivers
19. Intratumoral Cancer Therapies Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.